Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks  from a “buy” ranking to a “hold” score in a research note released to financiers on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It concentrates on uncovering and developing little particle drug candidates to deal with cancer cells. The Business‘s products under different stages of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research analysts also recently talked about the business. Noble Financial editioned a “get” score as well as provided a $11.00 rate purpose on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and set a “purchase” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day relocating average rate of $2.90 and also a two-hundred day relocating typical rate of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly earnings results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) incomes per share for the quarter, topping analysts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an adverse web margin of 8,294.27%. The firm had earnings of $0.06 million during the quarter, compared to the consensus price quote of $0.06 million. Throughout the same quarter in the prior year, the company posted ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will certainly publish -1.18 EPS for the present year.

A number of hedge funds have lately dealt shares of ONTX. GSA Capital Partners LLP purchased a brand-new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Resources Administration LP purchased a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP bought a brand-new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and also other institutional capitalists possess 13.36% of the business’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which participates in the identification and development of oncology therapeutics. It focuses on finding and developing small molecule medicine prospects to deal with cancer cells. The company was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Obtain a complimentary copy of the Zacks research report on Onconova Therapeutics (ONTX).

To learn more regarding research offerings from Zacks Investment Research, go to Zacks.com.

This instant information alert was produced by narrative science innovation and monetary data from Market in order to give readers with the fastest as well as most accurate coverage. This tale was assessed by Market’s editorial group before publication. 



Prior to you think about Onconova Therapeutics, you’ll wish to hear this.

Market keeps track of Wall Street’s top-rated as well as best doing research analysts as well as the stocks they suggest to their customers each day. Market has actually recognized the five stocks that cover analysts are silently murmuring to their customers to buy currently prior to the wider market catches on … and also Onconova Therapeutics wasn’t on the list.

While Onconova Therapeutics presently has a “Buy” score among analysts, premier experts think these 5 stocks are much better buys.